Ken Griffin Bio Line Rx Ltd. Call Options Transaction History

Citadel Advisors LLC

5 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2024 Aug 14, 2024	BUY	$0.56 - $0.86 $14,448 - $22,188	25,800 Added 107.05%	49,900 $28,000
Q1 2024 May 15, 2024	SELL	$1.03 - $1.56 $12,669 - $19,188	-12,300 Reduced 33.79%	24,100 $26,000
Q4 2023 Feb 14, 2024	SELL	$1.31 - $1.86 $82,137 - $116,622	-62,700 Reduced 63.27%	36,400 $57,000
Q3 2023 Nov 14, 2023	BUY	$1.23 - $2.45 $66,789 - $133,035	54,300 Added 121.21%	99,100 $180,000
Q2 2023 Aug 14, 2023	BUY	$0.96 - $1.78 $43,008 - $79,744	44,800 New	44,800 $71,000

4.29M

49.9K

122K

Ticker BLRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,524,500
Market Cap $39.4M
Description
BioLineRx Ltd., a clinical-stage biopharmaceutical development company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials ...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.